News | February 09, 2026
Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
Subscribe To Our Newsletter & Stay Updated
